BTCY Looking great with over 8% in bookable gains so far during our coverage this week. BRN our oil producer report from a couple weeks back has been doing well offering up over 18% in bookable gains with great earnings out. New NASDAQ report on a company we have never covered before coming March 3rd, 2022 right here to the breakout group first near market open!

Have a great weekend,

The Traders News Group

A copy of this week’s coverage included below

Biotres and Bioflux Should be the Product’s That Push Biotricity (BTCY) Into Eight Figure Annual Revenues Near-Term

Good day everyone,

The NASDAQ index tumbled 344 points in the Wednesday session, but BTCY stayed green all day hitting a high of $2.98/share and only fading in the last 30 minutes of trading. I’m excited to see how the company shares trade on a strong NASDAQ day.

We told you earlier that Biotricity, Inc. (NASDAQ: BTCY) just announced that it is now taking pre-orders for Biotres, the Company’s three-lead device designed to continuously record electro-cardiogram (ECG) data for early detection of cardiac arrhythmias. Pre-Orders begin on February 23, 2022, with units shipping April 1, 2022.

Current price $2.76/share (+3.37% at market close 2-23-22)

I looked at the Biotres pre-order form and this is what it said:

Available April 1, 2022! (I note that FYE23 begins on this date)

Biotres is a revolutionary 3 channel Holter and extended Holter patch device that enables you to bill all Holter codes, while reducing report turnaround time. Pre-order yours today. Designed to address the current limitations of existing Holter monitors technologies, Biotres offers the following feature set:

3 Channel Recording – A wearable Holter patch device that can provide continuous 3 channel recording of ECG (heart) data. All other known holter patch devices are 1 channel or 2 channels.

Small Form Factor – Overall 4.5″ x 3.5″ Central body is 2.25″ diameter.

Unified Portal – Utilizes the same portal as the Bioflux! One system for all your diagnostic needs!

Rechargeable Battery – It can be worn continuously for 48 hours, in connectivity mode, before needing to be charged for 1 hour, enabling continuous data collection for extended periods of time without any intervention, a distinction not possible with traditional Holter patch solutions.

Wireless Connectivity – Utilizes Bluetooth technology to offload data, reducing the time for diagnoses. Current Holter patch solutions can take up to a week before diagnoses are available due to manual data downloading and a lack of connectivity.
User-Friendly Design – Easy to understand and comfortable to wear during regular day-to-day activities.

Modular Design – Designed with the flexibility to support our strategy of adding future features and functionality to the Biotres platform.

Unique Business Model – the design of Biotres enables providers to bill directly, creating a revenue stream with a simplified workflow for providers while reducing risk and diagnostic turnaround time for patients.

IMPORTANT! PLEASE NOTE: Once you received your Biotres and start using it, you will be on a flat rate model and will be charged at $125 per month per device. Biotres is a profit center after the first Holter study use! (that’s a $1,500 annual charge)

The company has a network of 1,500 cardiac doctors in 25 states in 350 clinics & 500 offices representing 3 million patients. Biotricity focuses on clinics because 80% of cardiologists are in multi-care groups. Given that BTCY is committed to growing its sales force this year, I expect that number of customers could grow considerably. It is estimated there are over 33,000 cardiologists is the United States and more and more of them are turning to technology-as-a-service implementing remote cardiac data collection.

It would only take the deployment of 7,000 Biotres units to propel the company into an eight figure annual revenue level, and keep in mind, the company has other popular verticals as well.

The Traders News Group

original reports below

Biotricity (BTCY) Guides Toward FYE22 as a Revenue Record Breaker and How FYE23 Could Be Their Breakout Year with New Revenue Streams

Now Taking Pre-Orders for Biotres

Good day everyone,

After closing the Tuesday session at $2.67/share Biotricity, Inc. (NASDAQ: BTCY) gapped at the open to $2.81/share. The share price quickly gained to $2.92 in early trading.

Current price    $2.87/share (+ 7.49% as of 10:10 am EST 2-23-22)

In news released this morning, BTCY announced that it is now taking pre-orders for Biotres, the Company’s three-lead device designed to continuously record electro-cardiogram (ECG) data for early detection of cardiac arrhythmias. Pre-Orders begin on February 23, 2022, with units shipping April 1, 2022

Biotres is a wireless three lead cardiac holter monitoring device, an upgrade from the one lead standard currently used by cardiac physicians. Biotres can provide continuous recording of ECG heart data and remote data uploading,

BTCY has a FYE of March 30, so they are now operating in Q422. I urge you, as a part of your due diligence, to review the Q322 BTCY form 10-Q filed on February 14th. While I have given you the highlights, the full 10-Q has a lot of details about the company’s near-term development plans.

Stay tuned for our full report on BTCY,

The Traders News Group

original report below

Biotricity (BTCY) Reports Strong FYQ3 Results and Lays Out Plans for a Breakout Year Ahead

“Look at this local news story where Biotricity’s Bioflux Device saved this man’s life ––w

Good day everyone and welcome to our new group members,

Last month when we reported on Biotricity, Inc. (NASDAQ: BTCY) I indicated they would be releasing their earnings report in a few weeks. We got the Q3 earnings report (FYE is March 30) on February 14th, 2022 and once again, it was great news.

Current price $2.64/share

BTCY Continues to Achieve Key Milestones

More good news with a recent strong financial report.

The share price is the lowest level I’ve seen in the past nine months, creating what I believe is an anomalous opportunity.

BTCY shares had a high of $5.30/share eleven weeks ago. Returning to that level will represent over 100% in gains for our group from the current levels.

Q322 financial highlights include:

Revenue of $1.93 million, an increase of 93% year-over-year and sequentially 7% above the $1.8- million reported in Q2FY22.

Cash Position of $16.8 M at quarter end is their highest ever.

Scaling well – SG&A rose just 40%, R&D up 32%, compared with 93% revenue increase.

Net loss of $7.34 million or $0.15 per share, impacted by one-time derivative fair value and accretion expenses of $1.34 million during the quarter; excluding these non-recurring items would result in an adjusted net loss of $6.0 million or $0.12 per share.

On track for FYE22 triple digit revenue growth.

Here is the recent growth in BTCY revenues:
FYE 2019 $392K
FYE 2020 $1.41M +259%
FYE 2021 $3.38M +139%
FYE 2022 $7.42M +119% (assumes Q422 revenue is equal to Q322 revenue)

Those figures above represent a cumulative revenue gain, over only three years, of 1,890%. I am hard pressed to think of another company with that level of revenue gains, in that short a period.

Q322 operational milestones:

Bioheart was brought to market, a heart monitor now directly available to consumers on the company website or Amazon.

FDA 510(k) clearance of Biotres, a holter monitor for low-risk patients designed for comfort and long-term wear. It will work with the Bioflux Platform as an additional billable tool for cardiac physicians.

In December, the Company successfully completed a $12 million non-dilutive debt financing on favorable terms.

There is a potential looming market for BTCY products due to covid. As just reported in the Washington Post, recent studies show that people exposed to covid are experiencing irregular pulse rates even months after infection. The studies, published in Nature Medicine, indicate that the risk of cardiovascular disease increased substantially in the year following infection even in mild covid cases, including folks in their 30s and 40s.

Donald M. Lloyd-Jones, president of the American Heart Association has stated publicly “we are expecting a tidal wave of cardiovascular events in the coming years from direct and indirect causes of covid.” I haven’t had covid (knocking on my wooden desk now) but if I’m ever exposed to it I would go to the BTCY website and get a Bioheart Monitor considering the $199 cost a cheap investment in my health.

The NASDAQ index has dropped significantly and BTCY shares have dropped in lockstep with the index, but the four analysts covering BTCY haven’t budged in their opinions. All four analysts have a “buy” rating on the company with a consensus target of $6.75/share representing a 153% upside.

BTCY has experienced fantastic growth but stayed dedicated to building shareholder value as evidenced by maintaining their modest share structure with 49.8M shares outstanding and only 39.5M shares in the public float. Since insiders hold about 7.5M shares, their interest in shareholder value benefits them. Note that The Vanguard Group owns 4.3% of the outstanding shares.

Anticipated and upcoming FY22 catalysts for BTCY:

BIG ONE HERE – Introduction of Bioflux 2.0, the next gen of their flagship platform used by cardiac clinics.

Watch this local news story where Biotricity’s Bioflux Device saved a man’s life ––w
This man is alive because of the Bioflux device reporting a dangerous abnormal heart beat while he was sleeping at 11pm. When this device gets into the broader market, there could be much more stories like this equating to a massive revenue stream for Biotricity.

Growth in the company sales force to push the company cardiac ecosystem beyond the current 1500 cardiac doctors and twenty-six states.

The introduction of advanced ECG analysis software that will analyze accumulated data in seconds.

Commercialization of the Biotres holter monitor.

The current value of BTCY stock doesn’t seem to reflect their level of revenue growth, technology, or their clearly defined milestones and potential catalysts for the year ahead.

We will be back with an updated report soon,

The Traders News Group

Privacy Policy and Disclaimer

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties?

We do not sell your information to anyone. Please see our cookie policy below.

What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.

What do we use your information for?

When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.

We send periodic emails

The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.

How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.

Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.

Online Privacy Policy Policy

This online privacy policy applies to information collected through our website and social media platforms.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.

Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have previously been compensated up to twenty five thousand dollars cash via bank wire on several occasions for our distributed opinions on btcy. However, we have NOT been compensated in any way for this week’s mention of brn or btcy and we do not hold any form of equity positions in btcy or brn. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.